Screening for Cervical and Breast Cancer Among Women with Inflammatory Bowel Disease: A Population-based Study

Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Inflammatory Bowel Diseases (Impact Factor: 5.48). 01/2011; 17(8):1741-50. DOI: 10.1002/ibd.21567
Source: PubMed

ABSTRACT There are limited data on rates and predictors of cervical and/or breast cancer screening among women with inflammatory bowel disease (IBD). Immunosuppressant medications used to manage IBD may increase the risk of cervical cancer precursor lesions.
Women diagnosed with IBD prior to 2002 were matched to up to 10 Manitoba residents without the disease. Logistic regression analyses were performed to compare utilization of Papanicolaou (Pap) tests and mammograms in the two groups. Among women with IBD, we analyzed the differences in screening between those with and without exposure to immunosuppressant medications and/or corticosteroids and effect of age, socioeconomic status, prior diagnostic testing, and intensity of healthcare utilization.
In all, 54% of the 2344 women with IBD and 52% of the 15,333 controls had regular Pap tests between 2002 and 2008. In multivariate analyses, older age, lower socioeconomic status, lower intensity of healthcare utilization, Crohn's disease, and exposure to immunosuppressant medications were independent predictors of lower use of Pap testing. Although there were no significant differences in the use of mammograms in women with or without IBD or among women with IBD with or without exposure to immunosuppressant medications, only 47% of women with IBD in the target age group had mammograms regularly.
Despite a need for higher testing, women with IBD on immunosuppressant medications are less likely to undergo Pap testing. Healthcare providers involved in the care of women with IBD need to remind these individuals about regular preventive care.

  • [Show abstract] [Hide abstract]
    ABSTRACT: : This review describes the history of U.S. government funding for surveillance programs in inflammatory bowel diseases (IBD), provides current estimates of the incidence and prevalence of IBD in the United States, and enumerates a number of challenges faced by current and future IBD surveillance programs. A rationale for expanding the focus of IBD surveillance beyond counts of incidence and prevalence, to provide a greater understanding of the burden of IBD, disease etiology, and pathogenesis, is provided. Lessons learned from other countries are summarized, in addition to potential resources that may be used to optimize a new form of IBD surveillance in the United States. A consensus recommendation on the goals and available resources for a new model for disease surveillance are provided. This new model should focus on "surveillance of the burden of disease," including (1) natural history of disease and (2) outcomes and complications of the disease and/or treatments.
    Inflammatory Bowel Diseases 11/2013; 20(2). DOI:10.1097/01.MIB.0000435441.30107.8b · 5.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Patients with inflammatory bowel diseases (IBDs) are at increased risk of colorectal cancer (CRC), but the risk varies between different studies and seems to be decreasing. The cumulative risk of CRC has been reported to be 1%, 2%, and 5% after 10, 20, and over 20 years of disease duration, respectively, in recent meta-analysis. Disease duration and grade of inflammation are the main driving forces of dysplasia and CRC development. Also, the risk of extraintestinal cancers is increased in IBD, where the degree of immunosuppression and its duration are the most important risk factors. Most important extraintestinal malignancies are lymphomas and non-melanoma skin cancers, both of which are increased in patients receiving thiopurines. Also, extraintestinal manifestations or concomitant diseases such as primary sclerosing cholangitis predispose IBD patients to malignancies such as cholangiocarcinoma. History of previous cancer increases the risk of developing either new or recurrent cancers and should be taken into account when choosing therapy and planning surveillance. Dysplasia and cancer screening and surveillance must be individualized according to patients' risk factors. Malignancies are the second most common cause of death after cardiovascular diseases in both genders in patients with IBD.
    Scandinavian Journal of Gastroenterology 01/2015; 50(1):81-9. DOI:10.3109/00365521.2014.992041 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: & Aims: We examined the risk of cervical neoplasia (dysplasia or cancer) in women with ulcerative colitis (UC) or Crohn's disease (CD). We also calculated the reverse-the risk for diagnosis with cervical neoplasia before development of inflammatory bowel disease (IBD).
    Clinical Gastroenterology and Hepatology 07/2014; DOI:10.1016/j.cgh.2014.07.036 · 6.53 Impact Factor

Full-text (2 Sources)

Available from
Dec 25, 2014